Glenmark Launches Kwitz - a Nicotine Replacement Therapy in India

MUMBAI, November 27, 2017 /PRNewswire/ --

- Kwitz® helps smokers in Smoking Cessation and supports the individual to achieve a smoke-free life

- Kwitz® is a Nicotine Replacement Therapy (NRT) that helps reduce craving to smoke over three months

Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced the launch of Kwitz®, a medically approved nicotine replacement therapy that helps smokers embark on a step by step journey towards a smoke-free life. Kwitz® Nicotine gum will be available in two variants. Kwitz® 2mg will be available as an OTC product for smokers having less than 20 cigarettes per day and Kwitz® 4mg for smokers consuming more than 20 cigarettes per day as prescription product.

     (Photo: )

Kwitz®, a Nicotine Replacement Therapy (NRT) product, provides treatment to smokers who are willing to get on a journey to quit smoking altogether by reducing dependency on cigarettes gradually. NRTs substitute a small quantity of nicotine otherwise obtained from cigarette smoking, with clean nicotine in moderate amounts to help satiate the cravings, thereby assisting an individual in controlling the withdrawal symptoms and reduce chances of a relapse. Unlike tobacco smoke, it allows users to access nicotine, which is free from harmful chemicals like carbon monoxide, tar and other irritants hence providing a safe way for smokers to achieve a smoke-free life.

On the occasion of the launch Sujesh Vasudevan, President, and Head - India, Middle East and Africa, Glenmark Pharmaceuticals Ltd, said, "Glenmark is proud to bring Kwitz®, a nicotine replacement therapy in India. This product will help smokers achieve a healthier life by quitting tobacco smoking. We hope that Kwitz® will help individuals find a sustainable way to stop smoking in an easy step by step process." He further added, "Kwitz® is not just a product but a helping hand and support system for those who would want to quit smoking completely, thereby helping the individual and those who are around them."

WHO estimates that tobacco use (smoking and smokeless) currently causes about six million deaths and many of these are known to occur prematurely. The majority of the world's smoker population (80%) lives in low or middle-income countries, and smoking among males are found to be ten times higher than women across 49 countries. On an average, 12 years of life years are lost due to smoking. If the current worldwide smoking patterns were to persist, about 10 million deaths would occur per year from smoking by 2020.

In India, approximately 2,200 people die every day from tobacco-related diseases, and World Health Organization (WHO) predicts that the death toll will cross 1.5 million annually by 2020. Oral Tobacco consumption is highest in India. The economic burden on the country is approximately Rs. 2.5 million through direct medicinal costs, absenteeism for treatment and loss of income due to premature death due to tobacco-related diseases.

About Glenmark ShwaaS: 

Glenmark is committed to making the lives of patients better. It has consistently introduced new products to address conditions like allergic rhinitis, idiopathic pulmonary fibrosis, and asthma & COPD.

Glenmark has focused on introducing innovation-driven products in respiratory which help to improve the lives of patients. Glenmark has launched India's first digital dose inhaler - Digihaler and India's First Glycopyrronium which is a fast-acting dry powder inhaler under the brand - Airz.

About Glenmark Pharmaceuticals Ltd: 

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2017). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the U.S. and Western European markets. The API business sells its products in over 80 countries, including the U.S., various countries in the EU, South America and India.

Source -  

  • Rajkumar P, et al. BMJ Open 2017
  • WHO global report on trends in prevalence of tobacco smoking 2015
  • Prevalence of COPD in non smokers_LungIndia_2017
  • Salvi S, Agarwal A. India needs a national COPD prevention and Control program. J Assoc Physicians India 2012
  • ASH Fact Sheet on Stopping smoking: benefits and aids to quitting; September 2014
  • Benowitz N. L. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annu Rev Pharmacol Toxicol; 49; 57-71; 2009

For further information, please contact:
Ramkumar Uppara,,
Sr Manager - Corporate Communication,
Glenmark Pharmaceuticals

SOURCE Glenmark Pharmaceuticals Ltd


Get content for your website

Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Start today.



Contact PR Newswire

Send us an email at or call us at +91 22 6169 6000



Become a PR Newswire client

Request more information about PR Newswire products & services or call us at +91 22 6169 6000


  1. Products & Services
  2. Knowledge Centre
  3. Browse News Releases
  4. Contact PR Newswire